Innovative Molecules Expands Virology Pipeline with Novel EBV Antiviral Program
Innovative Molecules GmbH, a clinical-stage biopharmaceutical company focused on herpesvirus-mediated diseases, has announced the advancement of its virology pipeline with the addition of a novel Epstein-Barr Virus (EBV) antiviral program. This program, which includes several highly potent, directly acting targeted polymerase inhibitors, is slated to enter Phase 1 trials in 2027.
EBV is linked to a variety of serious health issues, such as lymphoproliferative disorders, transplant-related complications, and autoimmune conditions, while the current options for targeted antiviral treatments remain limited. The new program signifies a significant expansion of Innovative Molecules' activities in treating herpesvirus-associated diseases and further enhances the company's focus on developing differentiated antiviral therapeutics to meet substantial unmet medical needs.
Florian Vogel, CEO of Innovative Molecules, stated, "EBV is an increasingly important therapeutic area with substantial medical need, while growing momentum in both scientific research and therapeutic development. The addition of this program marks an important step in the continued expansion of our antiviral pipeline and reinforces our commitment to advancing innovative therapeutic approaches for serious viral diseases."
The EBV program aligns with Innovative Molecules' broader strategy of building a focused portfolio of differentiated virology assets that have the potential to address high-value indications with limited existing treatment options.
Innovative Molecules GmbH, based in Munich, Germany, aims to develop differentiated antiviral therapies for diseases associated with herpesviruses. The company is advancing a pipeline of novel therapeutics targeted at significant unmet medical needs among severe and underserved patient populations. Its lead program, adibelivir (IM-250), is a selective helicase-primase inhibitor being developed for the treatment of Herpes simplex virus (HSV)-mediated diseases, while the company continues to expand its virology pipeline through innovative approaches to additional herpesvirus indications, including Epstein-Barr Virus (EBV).